8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Data indicate that the use of prophylactic granulocyte colony-stimulating factors (G-CSFs) for chemotherapy-induced febrile neutropenia (FN) in routine practice is not consistent with guideline recommendations. The initiative “supportive care for febrile neutropenia prevention and appropriateness of G-CFS use” was undertaken to address the issue of inappropriate prescription of G-CSFs and to improve guideline adherence in the treatment of FN.

          Methods

          In a two-round Delphi procedure, 36 medical oncologists reviewed clinically relevant recommendations on risk assessment, the appropriate use of G-CSFs, and the prevention of FN based on available literature and individual clinical expertise.

          Results

          The consensus was reached on 16 out of 38 recommendations, which are backed by evidence from randomised clinical trials and routine clinical practice. The medical oncologists agreed that the severity of neutropenia depends on patients’ characteristics and chemotherapy intensity, and therefore, the risk of severe neutropenia or FN should be assessed at each chemotherapy cycle so as to initiate prophylaxis with G-CSFs if required. The use of biosimilar G-CSFs, with similar efficacy and safety profiles to the originator biologic, has improved the availability and sustainability of cancer care. The timing of supportive therapy is crucial; for example, long-acting G-CSF should be administered 24–72 h after chemotherapy administration. Each biological agent has a recommended administration dose and duration, and it is important to follow these recommendations to avoid complications associated with under-prophylaxis.

          Conclusion

          It is hoped that these statements will help to increase adherence to guideline recommendations for appropriate G-CSF use and improve patient care.

          Supplementary Information

          The online version contains supplementary material available at 10.1007/s00520-022-07430-7.

          Related collections

          Most cited references51

          • Record: found
          • Abstract: found
          • Article: not found

          The Delphi Technique: Making Sense of Consensus

          The Delphi technique is a widely used and accepted method for gathering data from respondents within their domain of expertise. The technique is designed as a group communication process which aims to achieve a convergence of opinion on a specific real-world issue. The Delphi process has been used in various fields of study such as program planning, needs assessment, policy determination, and resource utilization to develop a full range of alternatives, explore or expose underlying assumptions, as well as correlate judgments on a topic spanning a wide range of disciplines. The Delphi technique is well suited as a method for consensus-building by using a series of questionnaires delivered using multiple iterations to collect data from a panel of selected subjects. Subject selection, time frames for conducting and completing a study, the possibility of low response rates, and unintentionally guiding feedback from the respondent group are areas which should be considered when designing and implementing a Delphi study. Accessed 68,465 times on https://pareonline.net from August 30, 2007 to December 31, 2019. For downloads from January 1, 2020 forward, please click on the PlumX Metrics link to the right.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

            Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally advanced stage disease. We aimed to assess the antitumour activity and safety of neoadjuvant chemoimmunotherapy for resectable stage IIIA NSCLC.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.

                Bookmark

                Author and article information

                Contributors
                rosti.giovanni@gmail.com
                Journal
                Support Care Cancer
                Support Care Cancer
                Supportive Care in Cancer
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0941-4355
                1433-7339
                5 November 2022
                5 November 2022
                2022
                : 30
                : 12
                : 9877-9888
                Affiliations
                [1 ]GRID grid.10438.3e, ISNI 0000 0001 2178 8421, Department of Human Pathology, Scientific Direction of Oncology, , University of Messina, A.O. Papardo, ; Messina, Italy
                [2 ]GRID grid.24704.35, ISNI 0000 0004 1759 9494, Clinical Oncology Unit, , Careggi University Hospital, ; Florence, Italy
                [3 ]GRID grid.8404.8, ISNI 0000 0004 1757 2304, Department of Experimental and Clinical Medicine, , University of Florence, ; Florence, Italy
                [4 ]Department of Internal Medicine and Medical Oncology, ASST of Pavia, Pavia, Italy
                [5 ]LIUC University, Castellanza, Varese, Italy
                [6 ]GRID grid.508451.d, ISNI 0000 0004 1760 8805, Department of Breast and Thoracic Oncology, , Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, ; Napoli, Italy
                [7 ]GRID grid.419457.a, ISNI 0000 0004 1758 0179, Istituto Dermopatico Dell’Immacolata, IDI-IRCCS, ; Rome, Italy
                [8 ]Medical Oncology Unit, Comprehensive Cancer Centre, AULS-IRRCS Reggio Emilia, Reggio Emilia, Italy
                [9 ]GRID grid.419425.f, ISNI 0000 0004 1760 3027, Medical Oncology Fondazione IRCCS Policlinico San Matteo, ; Viale Camillo Golgi, 19, 27100 Pavia, PV Italy
                Author information
                http://orcid.org/0000-0003-2074-2418
                http://orcid.org/0000-0003-3349-5604
                http://orcid.org/0000-0001-9009-1572
                http://orcid.org/0000-0002-9064-8761
                http://orcid.org/0000-0002-3159-5268
                http://orcid.org/0000-0003-2097-2803
                Article
                7430
                10.1007/s00520-022-07430-7
                9715510
                36334157
                5cef5433-a857-4666-9a2e-4a7ef9ed2d48
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 12 April 2022
                : 23 October 2022
                Categories
                Original Article
                Custom metadata
                © Springer-Verlag GmbH Germany, part of Springer Nature 2022

                Oncology & Radiotherapy
                chemotherapy,consensus,febrile neutropenia,granulocyte colony-stimulating factor,supportive therapy

                Comments

                Comment on this article